Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Ahearn TU, et al. Among authors: ebot em. Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112. Carcinogenesis. 2018. PMID: 30165429 Free PMC article. Clinical Trial.
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation.
Sivakumar S, Moore JA, Montesion M, Sharaf R, Lin DI, Colón CI, Fleishmann Z, Ebot EM, Newberg JY, Mills JM, Hegde PS, Pan Q, Dowlati A, Frampton GM, Sage J, Lovly CM. Sivakumar S, et al. Among authors: ebot em. Cancer Discov. 2023 Jul 7;13(7):1572-1591. doi: 10.1158/2159-8290.CD-22-0620. Cancer Discov. 2023. PMID: 37062002 Free PMC article.
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, Baden J. He J, et al. Among authors: ebot em. J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339. J Immunother Cancer. 2023. PMID: 38035725 Free PMC article. Clinical Trial.
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.
Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghahi A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN. Richardson DL, et al. Among authors: ebot e. Clin Cancer Res. 2024 Oct 15;30(20):4644-4653. doi: 10.1158/1078-0432.CCR-24-1225. Clin Cancer Res. 2024. PMID: 39078736 Free PMC article.
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Chen KT, Madison R, Moore J, Jin D, Fleischmann Z, Newberg J, Schrock A, Bhardwaj N, Lofgren KT, He J, Frampton G, Hegde P, Fabrizio D, Pishvaian MJ, Ebot E, Singhi A, Sokol E. Chen KT, et al. Among authors: ebot e. Oncologist. 2023 Aug 3;28(8):691-698. doi: 10.1093/oncolo/oyad178. Oncologist. 2023. PMID: 37354528 Free PMC article.
33 results